Delivering More of an Injectable Human Recombinant Collagen III
Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating
Myocardial Infarction

J 2020

Delivering More of an Injectable Human Recombinant Collagen III Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating Myocardial Infarction

PUPKAITE, J; Veronika SEDLÁKOVÁ; CE CIMENCI; M BAK; S MCLAUGHLIN et al.

Základní údaje

Originální název

Delivering More of an Injectable Human Recombinant Collagen III Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating Myocardial Infarction

Autoři

PUPKAITE, J; Veronika SEDLÁKOVÁ; CE CIMENCI; M BAK; S MCLAUGHLIN; M RUEL; EI ALARCON a EJ SUURONEN

Vydání

ACS BIOMATERIALS SCIENCE & ENGINEERING, WASHINGTON, AMER CHEMICAL SOC, 2020, 2373-9878

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.749

Označené pro přenos do RIV

DOI

https://doi.org/10.1021/acsbiomaterials.0c00418

UT WoS

000551355300048

Klíčová slova anglicky

myocardial infarction; injectable hydrogel; collagen type III; scar; vascularization

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 1. 2022 10:05, MUDr. Veronika Sedláková, Ph.D.

Anotace

V originále

Injectable hydrogels are a promising method to enhance repair in the heart after myocardial infarction (MI). However, few studies have compared different strategies for the application of biomaterial treatments. In this study, we use a clinically relevant mouse MI model to assess the therapeutic efficacy of different treatment protocols for intramyocardial injection of a recombinant human collagen III (rHCIII) thermoresponsive hydrogel. Comparing a single hydrogel injection at an early time point (3 h) versus injections at multiple time points (3 h, 1 week, and 2 weeks) post-MI revealed that the single injection group led to superior cardiac function, reduced scar size and inflammation, and increased vascularization. Omitting the 3 h time point and delivering the hydrogel at 1 and 2 weeks post-MI led to poorer cardiac function. The positive effects of the single time point injection (3 h) on scar size and vascular density were lost when the hydrogel's collagen concentration was increased from 1% to 2%, and it did not confer any additional functional improvement. This study shows that early treatment with a rHCIII hydrogel can improve cardiac function post-MI but that injecting more rHCIII (by increased concentration or more over time) can reduce its efficacy, thus highlighting the importance of investigating optimal treatment strategies of biomaterial therapy for MI.

Citovat

PUPKAITE, J; Veronika SEDLÁKOVÁ; CE CIMENCI; M BAK; S MCLAUGHLIN; M RUEL; EI ALARCON a EJ SUURONEN. Delivering More of an Injectable Human Recombinant Collagen III Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating Myocardial Infarction. ACS BIOMATERIALS SCIENCE & ENGINEERING. WASHINGTON: AMER CHEMICAL SOC, 2020, roč. 6, č. 7, s. 4256-4265. ISSN 2373-9878. Dostupné z: https://doi.org/10.1021/acsbiomaterials.0c00418.

@article{1703799,
   author = {Pupkaite, J and Sedláková, Veronika and Cimenci, CE and Bak, M and McLaughlin, S and Ruel, M and Alarcon, EI and Suuronen, EJ},
   article_location = {WASHINGTON},
   article_number = {7},
   doi = {https://doi.org/10.1021/acsbiomaterials.0c00418},
   keywords = {myocardial infarction; injectable hydrogel; collagen type III; scar; vascularization},
   language = {eng},
   issn = {2373-9878},
   journal = {ACS BIOMATERIALS SCIENCE & ENGINEERING},
   title = {Delivering More of an Injectable Human Recombinant Collagen III Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating Myocardial Infarction},
   volume = {6},
   year = {2020}
}

TY  - JOUR
ID  - 1703799
AU  - Pupkaite, J - Sedláková, Veronika - Cimenci, CE - Bak, M - McLaughlin, S - Ruel, M - Alarcon, EI - Suuronen, EJ
PY  - 2020
TI  - Delivering More of an Injectable Human Recombinant Collagen III Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating Myocardial Infarction
JF  - ACS BIOMATERIALS SCIENCE & ENGINEERING
VL  - 6
IS  - 7
SP  - 4256-4265
EP  - 4256-4265
PB  - AMER CHEMICAL SOC
SN  - 23739878
KW  - myocardial infarction
KW  - injectable hydrogel
KW  - collagen type III
KW  - scar
KW  - vascularization
N2  - Injectable hydrogels are a promising method to enhance repair in the heart after myocardial infarction (MI). However, few studies have compared different strategies for the application of biomaterial treatments. In this study, we use a clinically relevant mouse MI model to assess the therapeutic efficacy of different treatment protocols for intramyocardial injection of a recombinant human collagen III (rHCIII) thermoresponsive hydrogel. Comparing a single hydrogel injection at an early time point (3 h) versus injections at multiple time points (3 h, 1 week, and 2 weeks) post-MI revealed that the single injection group led to superior cardiac function, reduced scar size and inflammation, and increased vascularization. Omitting the 3 h time point and delivering the hydrogel at 1 and 2 weeks post-MI led to poorer cardiac function. The positive effects of the single time point injection (3 h) on scar size and vascular density were lost when the hydrogel's collagen concentration was increased from 1% to 2%, and it did not confer any additional functional improvement. This study shows that early treatment with a rHCIII hydrogel can improve cardiac function post-MI but that injecting more rHCIII (by increased concentration or more over time) can reduce its efficacy, thus highlighting the importance of investigating optimal treatment strategies of biomaterial therapy for MI.
ER  -

PUPKAITE, J; Veronika SEDLÁKOVÁ; CE CIMENCI; M BAK; S MCLAUGHLIN; M RUEL; EI ALARCON a EJ SUURONEN. Delivering More of an Injectable Human Recombinant Collagen III Hydrogel Does Not Improve Its Therapeutic Efficacy for Treating Myocardial Infarction. \textit{ACS BIOMATERIALS SCIENCE \&{}amp; ENGINEERING}. WASHINGTON: AMER CHEMICAL SOC, 2020, roč.~6, č.~7, s.~4256-4265. ISSN~2373-9878. Dostupné z: https://doi.org/10.1021/acsbiomaterials.0c00418.

Přehled o publikaci